CDNA:NSD-CareDx Inc. (USD)

EQUITY | Diagnostics & Research | NASDAQ Global Market

Last Closing

USD 14.61

Change

+0.22 (+1.53)%

Market Cap

USD 0.08B

Volume

0.62M

Analyst Target

USD 44.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

CareDx Inc is a commercial stage company. The Company develops, markets and delivers a diagnostic surveillance solution for heart transplant recipients to help clinicians make personalized treatment decisions throughout a transplant patient's lifetime.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-25 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

+5.35 (+1.09%)

USD 41.65B
ICLR ICON PLC

+0.24 (+0.08%)

USD 26.38B
ILMN Illumina Inc

+0.78 (+0.74%)

USD 17.24B
NTRA Natera Inc

-1.38 (-1.24%)

USD 13.49B
MEDP Medpace Holdings Inc

+19.01 (+4.69%)

USD 12.38B
EXAS EXACT Sciences Corporation

+0.33 (+0.75%)

USD 7.74B
RDNT RadNet Inc

+0.78 (+1.34%)

USD 4.31B
GH Guardant Health Inc

-0.34 (-1.16%)

USD 3.66B
NEOG Neogen Corporation

-0.03 (-0.19%)

USD 3.63B
SHC Sotera Health Co

+0.07 (+0.59%)

USD 3.21B

ETFs Containing CDNA

ARCG:LSE ARK Genomic Revolution UC.. 6.28 % 0.00 %

-5.63 (-1.60%)

USD 2.30M
ARKG 0.00 % 0.75 %

N/A

N/A
JFWD Jacob Forward ETF 0.00 % 0.00 %

+0.06 (+-1.60%)

USD 2.68M

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 21.75% 80% B- 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.75% 80% B- 84% B
Trailing 12 Months  
Capital Gain 68.51% 91% A- 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 68.51% 91% A- 93% A
Trailing 5 Years  
Capital Gain -59.38% 48% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.38% 48% F 23% F
Average Annual (5 Year Horizon)  
Capital Gain 17.23% 68% D+ 76% C+
Dividend Return 17.23% 68% D+ 75% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 105.57% 26% F 15% F
Risk Adjusted Return 16.32% 64% D 53% F
Market Capitalization 0.08B 65% D 68% D+

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 1.69 53% 53%
Price / Cash Flow Ratio -39.01 92% 93%
Price/Free Cash Flow Ratio -2.82 61% 71%
Management Effectiveness  
Return on Equity -54.18% 45% 30%
Return on Invested Capital -29.48% 60% 30%
Return on Assets -12.63% 57% 32%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector